Skip to content
Flagship Biosciences
  • About
    • Process
    • Company
    • Our Vision
    • Careers
  • Pharma
    • Image Analysis
    • IHC / IF / ISH Assays
    • Multiplex Assays
    • Data Analysis and Reporting
    • Consultation with Scientific Experts
    • Regulatory Strategy and Support
  • Clinical Diagnostics
    • Clinical Data
    • Approved Partner Program
    • Scientific Advisory Board
  • Technology
  • Resources
    • News
    • Blog
    • Events
    • Posters & Publications
    • Collateral
  • Contact Us

Posters & Publications

POSTER: Impact of adding Viagenpumatucel-L (HS-110) to Nivolumab in Non-Small Cell Lung Cancer (NSCLC) Patients with Low Levels of Tumor Infiltrating Lymphocytes

Summary View a scientific, collaborative success with our client, Heat Biologics, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 medical oncology

Read More »
September 28, 2020

POSTER: Image Analysis-Based Identification and Quantification of Macrophages in PD-L1 (22C3) Stained NSCLC Tissue Sections Without Additional Macrophage-Specific Staining

ABSTRACT PD-L1 positivity in tumor-associated macrophages has been related to a favorable response to anti-PD-1 and PD-L1 targeted therapies. This concept has driven interest in

Read More »
July 3, 2020

POSTER: Protein Tyrosine Kinase 7 (PTK7) Biomarker Analysis in Patients treated with PF-06647020, a PTK7 Antibody-Drug Conjugate (ADC), in a Phase I Dose Expansion Study

BACKGROUND F-06647020, an ADC comprising a humanized monoclonal antibody against PTK7, a cleavable valine-citrulline linker, and an auristatin payload, is being investigated in an ongoing

Read More »
December 17, 2019

POSTER: Comprehensive Image Analysis Of Immunostained NSCLC Tissues Provides Necessary Context For Immune Oncology Biomarker Profiling

ABSTRACT Manual pathology assessments of Immunohistochemistry (IHC) markers in immuneoncology (IO) is often challenging and results can be highly variable. Measuring biomarker presence in IO

Read More »
November 11, 2019

POSTER: Artificial Intelligence Assisted Macrophage Identification in Tumor Biopsies

BACKGROUND: Understanding response to immunotherapy requires accurate and complete characterization of tumor-associated immune cells in order to fully contextualize the immuno-oncology biomarker expression. Current standard

Read More »
November 1, 2019

POSTER: Analysis of Companion Diagnostic Potentials For Multifaceted PD-L1 Assays

ABSTRACT In vitro diagnostic (IVD) approvals of qualitative immunohistochemical (IHC) assays offer unique patient selection strategies by equipping pathologists with new tools to assess tumor

Read More »
November 1, 2019
⟨ Page1 Page2 Page3 Page4 Page5 ⟩

Recent Posts

  • White Paper: Tissue Image Analysis and Biomarker Assessment Implementation Benefits and ROI
  • Biomarkers Strategies and Implementation for Drug Development (Regulatory Webcast Summary)
  • Flagship Spotlight: Caroline Chandler
  • Pharma Tech Outlook Cover Story: Flagship Biosciences – Accelerating Drug Development
  • Flagship Spotlight: Brenna O’Neill

Resources

  • News
  • Blog
  • Events
  • Posters & Publications

READY TO TAKE THE NEXT STEP?

Start Your Consultation Today

Our Services

Pharma

Cell-based image analysis, assays, and partnership to advance clinical trials and regulatory acceptance.

Learn More

Clinical Diagnostics

Dependable clinical diagnostic testing to connect patients to individualized, immuno-oncology therapies.

Learn More

Related Resources

Blog

Posters & Publications

News

Flagship carefully tracks our tissue to ensure we can analyze every assay and stay on schedule.
Sr. Pharmaceutical Research Director
Sr. Pharmaceutical Research Director
We are trying to bridge from the discovery stage to clinical development. Flagship's pathologists and scientists provide critical input and the company helps us organize and analyze an incredible amount of data. I highly recommend Flagship for its expertise and support for drug development projects.
Biopharma Director
Biopharma Director
During clinical trials, I interact with our manufacturing, legal, pre-clinical, and biomarker teams. Our Flagship project manager understands our tight timeline and ensures delivery of the data we need, when we need it.
Biotech Pharmaceutical Operations Director
Biotech Pharmaceutical Operations Director
We are pleased to partner with Flagship Biosciences to integrate their machine learning/AI tools to provide cancer marker detection.
Laboratory Software Solutions Provider COO
Flagship’s image analysis experts are flexible and willing to work with us to develop projects that meet the changing needs of our clinical trials drug development.
Sr. Pharmaceutical Research Director
Flagship has a high reputation as a supplier of advanced IHC services and their CAP-CLIA environment is a perfect complement to our own testing facilities.
Global Oncology Research Database Provider CEO
The ease of leveraging Flagship’s powerful solution is yet another massive differentiator of the company. Clients need not have to change their existing workflows, investments in technology, or even the assays that they use.
CIO Review, Pharma and Life Sciences

About Flagship Biosciences

We are a multi-disciplinary team of pathologists, biologists, analysts, software engineers, and technicians who are committed to creating successful approaches which match patients with life-saving drugs.
Learn More >

Quick Links

  • Pharma
  • Clinical Diagnostics
  • Posters & Publications
  • Events
  • Careers
  • Contact Us
Menu
  • Pharma
  • Clinical Diagnostics
  • Posters & Publications
  • Events
  • Careers
  • Contact Us

Connect With Us

Linkedin
Envelope
7575 West 103rd, Suite 102 Westminster, CO 80021 303.325.5894
  • Copyright 2021 Flagship Biosciences Inc.
  • Sitemap
  • Privacy Policy
  • 7575 West 103rd, Suite 102, Westminster, CO 80021
Search for:
Close Menu

Start Your Consultation Today